Extended adjuvant neratinib in HER2+/HR+ early breast cancer in clinical routine: Final results from the multi-national, prospective, observational study ELEANOR.

15. Januar 2026

D.I. Lüftner, R. Bartsch, U. Breitenstein, C. Jackisch, V. Mueller, M. Schmidt, M. Balic, G. Rinnerthaler, K. Zaman, M. Schwitter, D. Wrobel, D. Guth, M. Zaiss, J. Terhaag, L. Perlova-Griff, R. Wuerstlein, T. Schinköthe, C. Vannier, N. Harbeck.

Annals of Oncology, Volume 36, Supplement 2, 2025, Pages S326-S327, https://doi.org/10.1016/j.annonc.2025.08.728.

Abstract